Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Twist Bioscience Corp (TWST)

Twist Bioscience prices upsized $300.0 million stock offering at $96.00 per share

Neutral Impact 3 of 5 financing Written later

Twist Bioscience priced an upsized public offering of 3,125,000 common shares at $96.00 per share on August 4, 2026, for expected gross proceeds of $300.0 million. On August 5, 2026, the underwriters exercised in full their option to buy 468,750 additional shares, and the company expects net proceeds of about $327.1 million, with closing expected on or about August 6, 2026. The company says it will use the proceeds, together with existing cash, for research and development, manufacturing capacity expansion, product offerings, and working capital.

Key points

  • Priced 3,125,000 shares at $96.00 per share, with expected gross proceeds of $300.0 million (August 4, 2026)
  • Underwriters exercised in full their option to purchase 468,750 additional shares at $96.00 per share (August 5, 2026)
  • Expected net proceeds of about $327.1 million, including the option shares; closing expected on or about August 6, 2026
  • Offering made under a Form S-3 automatic shelf registration filed June 18, 2026; Goldman Sachs, William Blair, Leerink Partners and Guggenheim are the underwriters

The filing

CompanyTwist Bioscience Corp (TWST)
Form8-K, current report
Filed with the SECAug 5, 2026, 5:27 PM ET
Accession number0001104659-26-091280

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.